Home › NDC Lookup › RxCUI directory › RxCUI 2536758

24 HR viloxazine 200 MG Extended Release Oral Capsule [Qelbree] — RxCUI 2536758

RxNorm drug concept · Semantic branded drug
RxCUI 2536758 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 15 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2536758
Official name24 HR viloxazine 200 MG Extended Release Oral Capsule [Qelbree]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as24 HR Qelbree 200 MG Extended Release Oral Capsule; Qelbree 200 MG 24HR Extended Release Oral Capsule
FDA products mapped3
Package NDCs mapped15
Reported Medicaid activity (SDUD)451,086 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Viloxazine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Qelbree contains viloxazine, and it's what's called a non-stimulant ADHD medication. Most people know ADHD medications as stimulants — things like Adderall or Ritalin — but Qelbree...
  • What exactly is Qelbree and how is it different from other ADHD medications?
  • It's a real and important warning, and you're right to ask. In clinical trials, people taking Qelbree reported suicidal thoughts or behaviors more often than those taking a placebo...
  • I heard there's a serious warning about suicidal thoughts — should I be worried?
📖 Read our full Viloxazine guide →

🕸️ Concept Web — How 24 HR viloxazine 200 MG Extended Release Oral Ca... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR viloxazine 200 MG Extended Release Oral Capsule [Qelbree] RxCUI 2536758

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Viloxazine 11196
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Qelbree 2536549
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Viloxazine Extended Release Oral Capsule 2536547
    • Viloxazine Oral Product 1160523
    • Viloxazine Pill 1160524
    • Viloxazine Extended Release Oral Capsule [Qelbree] 2536551
    • Qelbree Oral Product 2536552
    • Qelbree Pill 2536553
    • Extended Release Oral Capsule 316943
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Viloxazine 200 MG [Qelbree] SBDC · 2536757
  • Viloxazine Extended Release Oral Capsule [Qelbree] SBDF · 2536551
  • Qelbree Oral Product SBDG · 2536552
  • Qelbree Pill SBDG · 2536553
  • Qelbree BN · 2536549

📦 FDA Products & Package NDCs

3 products · 15 package NDCs
15 package NDCs map to RxCUI 2536758 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
17772-0131-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-01) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0131-07 7 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-07) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0131-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-30) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0131-60 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-60) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0131-90 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-90) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0132-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-01) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0132-07 7 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-07) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0132-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-30) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0132-60 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-60) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0132-90 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-90) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0133-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-01) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0133-07 7 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-07) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0133-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-30) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0133-60 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-60) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
17772-0133-90 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-90) QELBREE Supernus Pharmaceuticals, Inc 2021-04-02
Observed labelers: Supernus Pharmaceuticals, Inc (15) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.